Research Participation

Know which kind of record you are reading

A patient registry organizes information over time. An observational study measures health or function without assigning an experimental intervention. An interventional clinical trial assigns an intervention under a protocol to answer defined safety or efficacy questions. The same person or study network can appear in more than one kind of record, so the record type matters.

A study can continue follow-up after it stops accepting new participants. “Active, not recruiting” is therefore different from both “recruiting” and “completed.” A registry status can also be old even when its public page is still visible.

Read eligibility as protocol boundaries

Eligibility criteria protect participants and define the population whose data can answer the research question. Age, diagnosis, functional ability, prior treatment, geography, testing, and other health factors may all matter.

A public summary cannot determine eligibility. Registry criteria can be incomplete, change after an amendment, or be applied with details that only the study team can assess. A listed site does not by itself mean that site is currently screening participants.

Consent, burden, privacy, and withdrawal

Informed consent should explain the purpose, procedures, foreseeable risks, possible benefits, alternatives, privacy practices, costs or reimbursement, whom to contact, and the voluntary nature of participation. Children may also be asked for assent in addition to permission from a parent or guardian, depending on the protocol and local rules.

Useful questions include how often visits occur, what travel is required, which samples or records are collected, who may use the data, how long information is kept, whether individual results are returned, and what happens to previously collected data or samples after withdrawal. The study’s own consent materials control; this page does not summarize a specific consent form.

Expanded access and special access are separate pathways

The U.S. Food and Drug Administration describes expanded access as a potential route to an investigational medical product outside a clinical trial for certain patients with serious or immediately life-threatening conditions when requirements are met. The treating physician, company, review body, and FDA each have roles. The pathway does not require a company to provide a product.

Health Canada’s Special Access Program allows a health-care professional to request access to an unauthorized drug for a patient with a serious or life-threatening condition when conventional treatments have failed, are unsuitable, or are unavailable. Authorization is case-specific and does not mean the drug is approved or generally available.

Verify a possible opportunity

Start with the primary registry or regulator page. Record the status, source update date, responsible sponsor or institution, age range, study type, and whether the location itself is marked as recruiting. Then use the current contact route shown by that primary source.

Separate a sponsor’s future intention from an open study. A dated statement about a planned study is not a registry record, enrollment notice, expanded-access program, or approval. Recheck the source because research listings and access policies change.

• What is the exact registry identifier and record type?
• When did the responsible party last verify the status?
• Is the specific location marked as recruiting, and is that current?
• Which protocol criteria appear relevant, and which require study-team assessment?
• What procedures, travel, costs, privacy terms, and result-return rules apply?
• Is an access claim documented by the regulator, sponsor, and treating team rather than inferred from a trial listing?